The effectiveness of first-line chemotherapy based on pemetrexed has been extensively recorded in cases of NSCLC with ALK positive (66, 67) and the favorable safety profile of cisplatin plus pemetrexed followed by pemetrexed maintenance, which make it an acceptable choice as a control strategy for standard chemotherapy (35). The gene discussed is ALK; the disease is non-small cell lung carcinoma.